<?xml version="1.0" encoding="UTF-8"?>
<p id="p0450">Lu reported that remdesivir may have the greatest potential for the successful treatment of SARS-CoV-2, but the efficacy and safety of remdesivir in COVID-19 needs further evaluation [
 <xref rid="bib135" ref-type="bibr">135</xref>]. The antiviral efficiency of five FAD-approved drugs and two well-known broad-spectrum antiviral drugs have been studied and it has been found that remdesivir and chloroquine effectively inhibit SARS-CoV-2 
 <italic>in vitro</italic> [
 <xref rid="bib136" ref-type="bibr">136</xref>]. The New England Journal of Medicine reported that the first case of COVID-19 confirmed in the United States was treated with intravenous remdesivir and demonstrated clinical improvement [
 <xref rid="bib71" ref-type="bibr">71</xref>]. At present, a randomized, double-blind, placebo-controlled phase III clinical trial of remdesivir has been launched and already 761 confirmed cases have been enrolled [
 <xref rid="bib132" ref-type="bibr">132</xref>]. Lu also pointed out that there is no direct evidence that oseltamivir is effective in the treatment of SARS-CoV-2 [
 <xref rid="bib135" ref-type="bibr">135</xref>]. However, we found that oral oseltamivir or abidol has been used for suspected or confirmed SARS-CoV-2 cases.
</p>
